Sialorrhea in amyotrophic lateral sclerosis: A hypothesis of a new treatment - Botulinum toxin a injections of the parotid glands

Medical Hypotheses

Volumn 48, Issue 4, 1997, Pages 337-339

  Bushara, K O ^a  

^a University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; AUTONOMIC DENERVATION; AUTONOMIC GANGLION; DRUG EFFICACY; HUMAN; HYPERSALIVATION; NEUROMUSCULAR BLOCKING; PAROTID GLAND; PAROTITIS; PRIORITY JOURNAL; SALIVARY GLAND DISEASE;

EID: 0030998772     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(97)90103-1     Document Type: Article

References (17)

1. Rose F C. The management of motor neuron disease. J Exp Med Biol 1987; 209: 167-174.
2. Klara H K, Magoon E H. Side effects of use of Botulinum toxin for treatment of benign essential blepharospasm and hemifacial spasm. Ophthal Surg 1990; 21(5): 335-338.
3. Anderson T J, Rivest J, Stell R et al. Botulinum toxin treatment of spasmodic torticollis. J Roy Soc Med 1992; 85: 524-529.
4. Girlanda P, Vita G, Nicolosi C, Milone S, Messina C. Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system. J Neurol Neurosurg Psychiatr 1992; 55: 844-845.
5. Olney R K, Aminoff M J, Gelb D J, Lowenstein D H. Neuromuscular effects distant from the site of Botulinum neurotoxin injection. Neurology 1988; 38: 1780-1783.
6. Burgen A S, Dickens F, Zatman L J. The action of botulinum toxin on the neuromuscular junction. J Physiol 1949; 109: 10-24.
7. Schiavo G, Santucci A, Dasgupta B R et al. Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds. FEBS Lett 1993; 335(1): 99-103.13.
8. Dolly J O, Black J D, Williams R S, Melling J. Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediates its internalization. Nature 1984; 307: 457-460.8.
9. Molgo J, Comelia J X, Angaut-Petit D et al. Presynaptic actions of Botulinal neurotoxins at vertebrate neuromuscular junctions. J Physiol (Paris) 1990; 84: 152-166.
10. MacKenzie I, Bumstock G, Dolly J O. The effects of purified botulinum neurotoxin type A on cholinergic, adrenergic and non-adrenergic, atropine-resistant autonomic neuromuscular transmission. Neuroscience 1982; 7(4): 997-1006.
11. Bushara K O, Park D M. Botulinum toxin and sweating. J Neurol Neurosurg Psychiatr 1994; 57(11): 1437-1438.
12. Vita G, Girlanda P, Puglisi, Marabello L, Messina C. Cardiavascular reflex testing and single fibre electromyography in botulism. Arch Neurol 1987;44: 202-206.
13. Dickson E C, Shevky R. Studies on the manner in which the toxin of clostridium botulinum acts upon the body. 1. The effect upon the autonomic nervous system. J Exp Med 1923; 37: 711-731.
14. Hughes J M, Bulmenthal J R, Merson M H, Lombard G L, Dowell V R Jr, Gangarosa E J. Clinical features of type A and B food-borne botulism. Ann Intern Med 1981; 95: 442-443.
15. Shaari C M, George E F, Wu B L, Biller H F, Sanders I. Quantifying the spread of botulinum toxin through muscle fascia. Laryngoscope 1991; 101(9): 960-964.
16. Mann A C. Localised autonomic failure due to botulinum toxin injection. J Neurol Neurosurg Psychiatr 1994; 57(11): 1320.
17. Bushara K O. Localised autonomic failure due to botulinum toxin injection. J Neurol Neurosurg Psychiatr (in press).